- Home
- ELBM vs MREO Comparison
ELBM vs MREO Comparison
Compare ELBM & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELBM | MREO |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 52.5M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ELBM | MREO |
|---|---|---|
| Price | $0.65 | $0.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $2.15 | $1.50 |
| AVG Volume (30 Days) | 911.8K | ★ 1.5M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | $28.71 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.20 |
| 52 Week High | $8.70 | $2.94 |
Technical Indicators
Market Signals| Indicator | ELBM | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 36.51 |
| Support Level | $0.50 | $0.20 |
| Resistance Level | $0.71 | $0.36 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 55.73 | 25.67 |
Price Performance
Historical ComparisonAbout ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).